Clinical trials: Nonsmall Cell Lung Cancer Stage III
Carcinoma, Non-Squamous Non-Small Cell Lung
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This randomized Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+nab-paclitaxel…
- Trial name
- IMpower130 (NCT02367781)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Nab-Paclitaxel
- Where
- 132 sites in United States, Belgium and 6 more
- Volunteers
- 723 people
- Sponsor
- Hoffmann-La Roche
Esophageal Cancer, Lung Cancer
PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery
RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 positron emission tomography (PET) scans, may improve the ability to detect lung and esophageal cancer or their recurrence.
- Trial name
- NCT00002930
- Testing
- positron emission tomography, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Small Cell Lung Cancer, Pancreatic Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort…
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC
- Trial name
- NCT05631574
- Testing
- BMF-219
- Where
- 23 sites in United States, South Korea
- Volunteers
- 13 people
- Sponsor
- Biomea Fusion Inc.
Lung Cancer
Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Studying the proteins expressed in samples of blood and tissue from patients with cancer may help doctors identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
- Trial name
- NCT00989690
- Testing
- docetaxel, erlotinib hydrochloride, pemetrexed disodium
- Where
- Italy
- Volunteers
- 275 people
- Sponsor
- Istituto Scientifico H. San Raffaele
Lung Cancer, Lung Cancer Stage III
Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.
The introduction of maintenance immunotherapy with the anti PD-L1 inhibitor durvalumab opened a new therapeutic window for stage III NSCLC patients who achieve at least stable disease after chemo-radiation, as shown by the…
- Trial name
- NCT04364776
- Testing
- Durvalumab
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
NSCLC, Stage IIIA, EGF-R Negative Non-Small Cell Lung Cancer
A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations
This is a randomized, open-label study designed to evaluate the safety and efficacy of neoadjuvant PD-1 antibody plus chemotherapy followed by surgery in resectable stage IIIA non-small cell lung cancer.
- Conditions
- NSCLC, Stage IIIA, EGF-R Negative Non-Small Cell Lung Cancer, ALK Negative NSCLC
- Trial name
- NCT05157776
- Testing
- PD-1 and chemotherapy
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Tongji University
Non-small Cell Lung Cancer
Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer
This study was designed to determine whether adjuvant vinorelbine plus cisplatin and endostar prolongs overall survival compare to vinorelbine plus cisplatin alone among patients with completely resected IB-IIIA non-small-cell…
- Trial name
- NCT00576914
- Testing
- recombinant human endostatin
- Where
- China
- Volunteers
- 1,108 people
- Sponsor
- Chinese Academy of Sciences
NSCLC (Non-small Cell Lung Carcinoma), Stage III
Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma
This is a prospective, single-arm, Phase II clinical study aimed at evaluating the efficacy and safety of 160mg fimonertinib in combination with definitive radiotherapy for patients with EGFR uncommon driver mutation-positive…
- Conditions
- NSCLC (Non-small Cell Lung Carcinoma), Stage III, EGFR Uncommon Mutations
- Trial name
- NCT07314216
- Testing
- Firmonertinib, Definitive Thoracic Radiotherapy
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Hunan Cancer Hospital
Non-small Cell Lung Cancer
Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)
The purpose of this research study is to determine the maximum tolerated dose of GT103 and investigate the safety and effectiveness of the study drug.
- Trial name
- NCT04314089
- Testing
- GT103
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Edward Patz
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Lung Cancer
Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether giving gefitinib after initial chemotherapy is effective in delaying the recurrence of…
- Trial name
- NCT00091156
- Testing
- gefitinib, adjuvant therapy
- Where
- 28 sites in Belgium, Cyprus and 3 more
- Volunteers
- 598 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation
This study assesses cardiovascular injury and cardiac fitness in patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (locally advanced) receiving model based personalized chemoradiation.
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT05010109
- Testing
- 6 Minute Walk Functional Test, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer
Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer
This is a Phase II, open-label trial of Taxotere® + ZD1839 in elderly patients with Stage III-b or IV NSCLC who have received no prior chemotherapy for metastatic disease.
- Trial name
- NCT00231465
- Testing
- docetaxel (Taxotere®), ZD1839
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lung Cancer (NSCLC)
A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC
Evaluate the efficacy and safety of neoadjuvant furmonertinib combined with anlotinib and chemotherapy in patients with resectable stage II-III EGFR mutation-positive non-small cell lung cancer.
- Trial name
- NCT06585644
- Testing
- Furmonertinib in combination with Anrotinib and chemotherapy
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Lung Cancer
Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00293332
- Testing
- bevacizumab, carboplatin, docetaxel
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of California, San Francisco
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer
This phase I trial studies the side effects and best dose of sapanisertib when given together with osimertinib in treating patients with stage IV EGFR mutation positive non-small cell lung cancer that has progressed after…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02503722
- Testing
- Laboratory Biomarker Analysis, Osimertinib, Pharmacological Study
- Where
- 5 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how…
- Trial name
- NCT02864992
- Testing
- Tepotinib
- Where
- 176 sites in United States, Austria and 13 more
- Volunteers
- 337 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Stage II-III Non-small Cell Lung Cancer
Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)
This is a randomized, controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of SBRT sequencial with Toripalimab and chemotherapy versus Toripalimab and chemotherapy for subjects with resectable…
- Trial name
- neoR-TORCH (NCT06437977)
- Testing
- SBRT, Toripalimab
- Where
- China
- Volunteers
- 478 people
- Sponsor
- Shanghai Chest Hospital
Non-Small Cell Lung Cancer
Iressa 2nd Line Phase III Study in Japan
In this study, among the patients with non-small cell lung cancer, those with metastasis or recurrence and previous treatment with chemotherapy will receive gefitinib or docetaxel, and we will compare the effectiveness and safety…
- Trial name
- NCT00252707
- Testing
- Gefitinib or Docetaxel
- Where
- 40 sites in Japan
- Volunteers
- 484 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer Stage III
Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC
Standard treatment for stage III Non-Small Cells Lung Cancer (NSCLC) not eligibile for surgery is concomitant chemoradiotherapy.
- Trial name
- BRIDGE (NCT04765709)
- Testing
- durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed), Durvalumab plus radiotherapy, durvalumab
- Where
- 3 sites in France, Italy and 1 more
- Volunteers
- 10 people
- Sponsor
- Mario Negri Institute for Pharmacological Research